'Product erlocip 150 mg' diaporamas de présentation

Buy Erlocip 150 mg

Buy Erlocip 150 mg is used as the first-line treatment of patients with pathological process non-small cell carcinoma (NSCLC) whose tumors have stratum protein receptor (EGFR) coding DNA nineteen deletions or coding DNA twenty-one (L858R) substitution mutations as detected by FDA. The upkeep treatment of patients with domestically advanced or pathological process non-small cell carcinoma whose illness has not progressed once four cycles of platinum-based first-line therapy.

90 views • 7 slides